Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated life-threatening complication. It is an adverse drug reaction caused by the generation of antibodies that activates platelet factor 4(PF-4) in the presence of heparin.
Heparin-Induced Thrombocytopenia (HIT) can lead to many thromboembolic complications, such as acute myocardial infarction, pulmonary embolism, deep venous thrombosis, thrombotic stroke and pulmonary embolism.
A number of laboratory tests like Enzyme-Linked Immunosorbent Assay (ELISA), Serotonin Release Assay (SRA), Enzyme Immunoassay (EIA), Heparin-Induced Platelet Activation (HIPA) Tests are now available to confirm the diagnosis of Heparin-induced thrombocytopenia (HIT) treatment. Heparin-Induced Thrombocytopenia (HIT) treatment can be mediated by three alternative anticoagulants. These include Lepirudin, Danaparoid and Argatroban.
These antithrombotic drugs are immediately active and are direct inhibitors of thrombin. They also inhibit thrombin generation and are routinely monitored. These drugs are monitored with ecarin the clotting time (ECT) for lepirudin, the activated clotting time (ACT) for argatroban, or anti?Xa assays for danaparoid.
However, consideration should be given towards the safety and efficacy of the alternative anticoagulant drug for the heparin-induced thrombocytopenia (HIT) treatment. The patient’s clinical status including renal and hepatic function, likely risks and benefits should be monitored during the heparin-induced thrombocytopenia (HIT) treatment.
Request Sample PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-10978
Heparin-Induced Thrombocytopenia (HIT) Treatment: Drivers and Restraints
Increase administration of various forms of heparin, an anticoagulant for the treatment of cardiovascular and orthopaedic surgery and invasive procedures increase the chances of heparin-induced thrombocytopenia, which drives the heparin-induced thrombocytopenia (HIT) market.
Heparin is widely being used in acute coronary syndromes, atrial fibrillation, venous thromboembolism, dialysis, peripheral occlusive disease, and during extracorporeal circulation which increase the chances of heparin-induced thrombocytopenia (HIT) and drives the market of heparin-induced thrombocytopenia (HIT) treatment.
About 12 million hospitalized patients in the USA, around one third in a year, are receiving heparin, which is expected to drive the heparin-induced thrombocytopenia (HIT) treatment market. However, due to the various complications of heparin-induced thrombocytopenia (HIT) treatment and side effects of the available drugs expected to restraints the heparin-induced thrombocytopenia (HIT) treatment market.
Heparin-Induced Thrombocytopenia (HIT) Treatment: Overview
The growth of heparin-induced thrombocytopenia (HIT) treatment market is expected to be high during forecasting periods due to the life-threatening complication of the disease. Increasing administration of heparin develops the possibilities of life-threatening heparin-induced thrombocytopenia (HIT), which will drive the heparin-induced thrombocytopenia (HIT) treatment market.
However, due to the less availability of sophisticated drugs and therapies, there is a huge opportunity among the key market players for the development of novel drug and therapies for the heparin-induced thrombocytopenia (HIT) treatment during the near forecasting periods
Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Region-wise Outlook
U.S. is expected as the largest regional market share in the heparin-induced thrombocytopenia (HIT) treatment market owing to high patient awareness levels, the presence of more number of market players, increasing awareness about heparin-induced thrombocytopenia (HIT) treatment and marketing activities in the region followed by Europe.
The heparin-induced thrombocytopenia (HIT) treatment market is expected to grow fastest in the Asia Pacific may because of the increasing prevalence of cardiovascular and acute coronary syndromes, thus boosting the market growth.
However, in the South Asian countries such as India and China, the opportunities to manufacture and distribute new heparin-induced thrombocytopenia (HIT) treatment drugs is expected to be higher due to large population and increasing incidence of heparin-induced thrombocytopenia during forecasting periods.
Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-10978
Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Key Market Participants
Key players of heparin-induced thrombocytopenia (HIT) treatment market includes Pfizer Inc., Alleviare Life Sciences Pvt. Ltd., ANDOZ, GlaxoSmithKline Plc., Eagle Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd., WEST-WARD, INC among others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (India, China ASEAN, Australia & New Zealand)
- The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA